Mirum Pharmaceuticals (NASDAQ:MIRM) Short Interest Update

Mirum Pharmaceuticals (NASDAQ:MIRM) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 38,000 shares, a decline of 32.5% from the August 30th total of 56,300 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 77,900 shares, the days-to-cover ratio is currently 0.5 days.

Mirum Pharmaceuticals stock traded down $0.58 during mid-day trading on Friday, reaching $8.85. 25,097 shares of the company traded hands, compared to its average volume of 38,082. The stock’s 50 day moving average price is $10.72. Mirum Pharmaceuticals has a 52-week low of $8.85 and a 52-week high of $15.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, August 28th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($1.83). As a group, sell-side analysts expect that Mirum Pharmaceuticals will post -3.3 EPS for the current fiscal year.

In other news, Director Laurent Fischer bought 4,650 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were bought at an average cost of $10.60 per share, with a total value of $49,290.00. Also, major shareholder Holdings A/S Novo bought 575,000 shares of the firm’s stock in a transaction that occurred on Monday, July 22nd. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $8,625,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 1,378,432 shares of company stock worth $20,587,684.

Several research analysts recently commented on MIRM shares. Evercore ISI began coverage on shares of Mirum Pharmaceuticals in a research note on Monday, August 12th. They issued an “outperform” rating and a $25.00 target price on the stock. Citigroup began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set a “buy” rating and a $21.00 price objective on the stock. Raymond James began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set an “outperform” rating and a $28.00 price objective on the stock. Guggenheim began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Roth Capital began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, August 12th. They set a “buy” rating and a $33.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average target price of $25.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Read More: Management Fee

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit